S
NTLA icon

SignatureFD’s Intellia Therapeutics NTLA Stock Holding History

SignatureFD’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Sell
1,417
-190
-12% -$2.66K ﹤0.01% 2254
2026
Q1 		$20.6K Buy
1,607
+40
+3% +$510 ﹤0.01% 2190
2025
Q4 		$14.1K Sell
1,567
-160
-9% -$2.2K ﹤0.01% 2267
2025
Q3 		$29.8K Hold
1,727
– – ﹤0.01% 1906
2025
Q2 		$16.2K Buy
1,727
+370
+27% +$3.04K ﹤0.01% 2155
2025
Q1 		$9.65K Sell
1,357
-332
-20% -$3.35K ﹤0.01% 2372
2024
Q4 		$19.7K Buy
1,689
+1,381
+448% +$21.6K ﹤0.01% 2071
2024
Q3 		$6.33K Sell
308
-163
-35% -$3.76K ﹤0.01% 2500
2024
Q2 		$10.5K Sell
471
-394
-46% -$9.38K ﹤0.01% 2241
2024
Q1 		$23.8K Sell
865
-727
-46% -$20.2K ﹤0.01% 1910
2023
Q4 		$48.5K Buy
1,592
+751
+89% +$21.6K ﹤0.01% 1482
2023
Q3 		$26.6K Buy
841
+133
+19% +$5.16K ﹤0.01% 1711
2023
Q2 		$28.9K Sell
708
-84
-11% -$3.41K ﹤0.01% 1698
2023
Q1 		$29.5K Buy
792
+474
+149% +$18.6K ﹤0.01% 1658
2022
Q4 		$11.1K Buy
318
+3
+1% +$143 ﹤0.01% 2100
2022
Q3 		$18K Buy
315
+26
+9% +$1.61K ﹤0.01% 1791
2022
Q2 		$15K Buy
289
+30
+12% +$1.52K ﹤0.01% 1925
2022
Q1 		$19K Sell
259
-26
-9% -$2.2K ﹤0.01% 1865
2021
Q4 		$34K Buy
285
+13
+5% +$1.63K ﹤0.01% 1528
2021
Q3 		$36K Sell
272
-43
-14% -$6.51K ﹤0.01% 1475
2021
Q2 		$51K Sell
315
-35
-10% -$2.73K ﹤0.01% 1260
2021
Q1 		$28K Buy
350
+100
+40% +$6.71K ﹤0.01% 1434
2020
Q4 		$14K Buy
250
+89
+55% +$3.23K ﹤0.01% 1578
2020
Q3 		$3K Buy
161
+61
+61% +$1.27K ﹤0.01% 2104
2020
Q2 		$2K Sell
100
-332
-77% -$5.64K ﹤0.01% 2156
2020
Q1 		$5K Buy
432
+329
+319% +$4.43K ﹤0.01% 1685
2019
Q4 		$2K Hold
103
– – ﹤0.01% 1900
2019
Q3 		$1K Hold
103
– – ﹤0.01% 1976
2019
Q2 		$2K Hold
103
– – ﹤0.01% 1773
2019
Q1 		$2K Buy
103
+3
+3% +$45 ﹤0.01% 1787
2018
Q4 		$1K Hold
100
– – ﹤0.01% 1845
2018
Q3 		$3K Sell
100
-450
-82% -$13.1K ﹤0.01% 1644
2018
Q2 		$15K Buy
550
+100
+22% +$2.42K ﹤0.01% 1270
2018
Q1 		$9K Buy
+450
New +$11.1K ﹤0.01% 1271

Other funds holding NTLA

CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
GITFIT
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) Warsaw, Poland $249M AUM 37.04% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

SignatureFD's NTLA Position: Q2 2026 in Review

SignatureFD reduced its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, selling an estimated $2.66K and leaving 1,417 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

SignatureFD first reported a position in NTLA in Q1 2018 and has held it in 34 quarters since. The position peaked at $51K in Q2 2021. 43 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • SignatureFD held 1,417 shares of Intellia Therapeutics worth $24K as of Q2 2026.
  • SignatureFD sold 190 Intellia Therapeutics shares in Q2 2026, an estimated $2.66K.
  • Intellia Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2254 holding.
  • SignatureFD first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 34 quarters since.
  • SignatureFD's Intellia Therapeutics position peaked at $51K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.